Pietraszek M H, Chabielska E, Buczko W
Department of Pharmacodynamics, Medical Academy Białystok, Poland.
Thromb Res. 1988 Apr 15;50(2):325-8. doi: 10.1016/0049-3848(88)90233-2.
Together with a mechanism such as activation of the coagulation system, vascular smooth muscle contraction and the activation of blood platelets are important processes in the hemostasis. Various calcium channel blockers besides those found to be vasodilators (1) have been shown to influence the functioning of blood platelets (2). They inhibit the aggregation induced by ADP, adrenaline, arachidonic acid or collagen (3). From these data it has been suggested that significant differences exist in the ability of calcium channel blockers to inhibit aggregatory responses (4). In order to elucidate further the possible role of calcium channel blockers in hemostasis we analyzed the effect of verapamil, diltiazem and nifedipine on the bleeding time, the amount of initial blood loss, platelet aggregation and some coagulation parameters in rats.
与凝血系统激活等机制一起,血管平滑肌收缩和血小板激活是止血过程中的重要环节。除了已发现具有血管舒张作用的钙通道阻滞剂外,其他多种钙通道阻滞剂已被证明会影响血小板功能。它们可抑制由二磷酸腺苷、肾上腺素、花生四烯酸或胶原诱导的聚集。从这些数据推测,钙通道阻滞剂抑制聚集反应的能力存在显著差异。为了进一步阐明钙通道阻滞剂在止血中的可能作用,我们分析了维拉帕米、地尔硫䓬和硝苯地平对大鼠出血时间、初始失血量、血小板聚集及一些凝血参数的影响。